Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$28.3M
88M shares
52-week range
$0.22 – $0.73
20% from low
Sector
ORTHOPEDIC, PROSTHETIC & SURGICAL APPLIANCES & SUPPLIES
Exchange
XASE
CS
Borrow rate
1.10%
Moderate
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $9.6M | $8.4M | $5.4M | $10.3M | $8.8M | $9.8M | $8.6M | $9.0M |
| Cost of revenue | $5.2M | $2.7M | $1.8M | $4.0M | $3.9M | $3.0M | $2.2M | $2.6M |
| Gross profit | $4.4M | $5.7M | $3.6M | $6.3M | $4.9M | $6.8M | $6.4M | $6.3M |
| Gross margin | 46.1% | 68.3% | 66.6% | 61.3% | 55.7% | 69.1% | 74.6% | 70.5% |
| R&D | $245.6K | $189.9K | $307.9K | $878.2K | $1.2M | $701.4K | $858.8K | $449.5K |
| Operating income | −$8.0M | −$4.0M | −$7.5M | −$7.4M | −$8.8M | −$7.1M | −$6.8M | −$5.7M |
| EBITDA | −$5.6M | −$7.4M | −$7.4M | −$6.8M | −$8.7M | −$6.9M | −$4.7M | −$5.5M |
| Net income | −$7.4M | −$7.5M | −$7.3M | −$6.8M | −$8.7M | −$6.9M | −$4.7M | −$5.7M |
| Net margin | -77.2% | -89.8% | -134.9% | -66.2% | -98.9% | -70.5% | -54.6% | -63.8% |
| EPS (diluted) | -0.21 | -0.17 | -0.12 | -0.10 | -0.12 | -0.10 | -0.06 | -0.07 |
Annual figures · source: Financial Modeling Prep
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $10M | $-0.04 | $-0.04–$-0.04 | 2 |
| 2027 | $11M | $-0.04 | $-0.04–$-0.03 | 2 |
Forward consensus · source: Financial Modeling Prep
Milestone Scientific Inc develops and commercializes proprietary computer-controlled drug delivery systems designed to enhance the safety, precision, and patient experience associated with subcutaneous injections and fluid aspiration procedures. The company's core technology platform, Dynamic Pressure Sensing (DPS) Technology, controls flow rate and measures pressure at the needle tip in real time. DPS Technology is incorporated into both the company's dental and medical products and supports clinical applications, including local anesthesia delivery, epidural space identification in regional anesthesia procedures, and intra-articular joint injections. It operates in two segments: Dental, which markets and sells its dental products, and Medical, markets and sells its medical products.
www.milestonescientific.comNo one on the platform currently holds MLSS.
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 82,497 | $23.8K |
| Execution date | Ratio |
|---|---|
| 2004-01-14 | 1-for-3reverse |
No one on the platform has traded MLSS yet.
| $40M |
| — |
| MYOMyomo, Inc. | $1.11 | +7.77% | $43M | — |
| NTRBNutriband Inc. | $3.21 | +4.90% | $39M | — |
Source: Financial Modeling Prep · peers by sector/industry
$MLSS An update on sales progress and reimbursement would be good about now..
View on StockTwits ↗$MLSS Instead of concentrating on streamlining the processes of this company and coming up with a First Class Sales Team their concentrating into bringing in more board members and rewarding themselves with immediate compensation. Show me the progress first with 2 to 4 positive quarters and a rising stock price and I'll gladly vote for compensation not beforehand.
View on StockTwits ↗$MLSS Directionless. Changing direction again. There is no hope for this company. Maybe a buyout will save us
View on StockTwits ↗$MLSS released a new Osser agreement cutting the former CEO's salary and adding two independent directors to the board.
View on StockTwits ↗$MLSS So what is happening here? Obviously Huge selling..By who? Why? Three weeks ago the stock was $.43 a share. It is now hovering at $.30.,which is a 30 % drop after climbing up from.26.The only significant news that we have had that could impact the stock to that degree was the announcement of the proposed proxy. Many people have commented that they believe it is premature, and we should not be diluting the stock to any degree at this point.Is that part of the selling issue going on here or is it low lifes like Lenny and Maxim dumping shares? clearly disappointing to see the share price slide back to below $.30.Maybe the CEO needs to release some news updates. But the fact is that the slide down has come after the release of the proxy vote proposal..
View on StockTwits ↗$MLSS Added, snagged half of that 55k ask upper 29s. This might go this week, next for sure.
View on StockTwits ↗$MLSS just look at the cycle, trading for pennies on the dollar with low volume. All it takes is one big buyer at this level. Company needs good guidance and needs to focus on the shareholder value.
View on StockTwits ↗$MLSS Not sure if this is shorting or Dumping.. We do have some shorts in here now. Believe it or not there are people that short penny stocks lol for real.Or do we have some people not happy with the proxy proposal and are dumping? Or both? Really surprising to be back at this price. We were at $.43 less than three weeks ago.
View on StockTwits ↗$MLSS looks like back to the last offering price if not news soon. Waiting til closer to meeting date to vote my shares to see if anything happens before then.
View on StockTwits ↗$MLSS just reclaimed its 200-day moving average, the line Wall Street watches to call a trend healthy again. Quiet name, real move under the surface.
View on StockTwits ↗$MLSS this might be one of those “why didn’t I take it” later
View on StockTwits ↗Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.
Trading at 3.0× sales vs its 7.1× historical median P/S.
Fair value ≈ $0.77 · price $0.32 today
Fair-value line = the stock's median historical P/S × sales per share. Price below the orange line = cheap vs its own history; above = expensive. Not investment advice.
Click to see transaction details on SEC.gov. Form 4s cover trades by officers, directors, and 10%+ owners, due within 2 business days of the trade.